Browsing: breast cancer

Two ESMO 2024 studies provided reassuring findings on breastfeeding for breast cancer survivors. A study of nearly 5,000 young BRCA mutation carriers and another of 518 women who interrupted treatment to have a baby both found no increased recurrence risk among those who breastfed their babies compared to those who did not breastfeed.

Roche announced today that Tecentriq® SC (atezolizumab) has been approved by the Singapore Health Sciences Authority (HSA) for all indications in which the intravenous (IV) formulation of Tecentriq has been previously approved, including certain types of lung, breast and liver cancer.4 Tecentriq SC is Roche’s fourth subcutaneous cancer therapy,5-7 and the world’s first injectable anti-PD-(L)1 cancer immunotherapy.

Cancer remains a significant public health concern in the Philippines, with the Department of Health (DOH) recording an estimated 153,751 cases in 2020. Among the various types of cancer, breast and cervical cancers stand out as major health challenges affecting women across different demographics and regions.

In conclusion, Herbosa’s advocacy epitomises a concerted effort to ensure accessibility and equity in healthcare access for all Filipinos. The DOH strives to catalyse a paradigm shift towards preventive care and bolster health outcomes nationwide. This is exhibited by advocating for the integration of essential preventive screenings into PhilHealth’s benefit packages and simplifying access for vulnerable populations such as PWDs. Guaranteeing that preventive screenings are readily accessible and financially feasible for all segments of society remains paramount to alleviating disease burden and propelling public health advancements in the Philippines. Herbosa’s initiatives underscore an unwavering commitment to realising universal health coverage and advancing health equity for every Filipino, irrespective of circumstance or background.

Speaker Ferdinand Martin Romualdez’s call for a comprehensive review of PhilHealth’s charter to extend patient benefits resonated strongly with the organisation’s vision. In response, PhilHealth affirmed its alignment with Speaker Martin’s directive, emphasising the urgent need to increase case packages across the board aggressively. Ledesma Jr. reiterated PhilHealth’s commitment to this cause, signalling a proactive approach to driving forward these enhancements in collaboration with key stakeholders.

A team from the NUS Centre for Cancer Research (N2CR) and the Department of Pathology at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), has made a significant discovery in the understanding of breast cancer’s resistance to chemotherapy. The study, led by Research Assistant Professor Leong Sai Mun, spanned over a decade and examined a large cohort of breast cancer patients to understand the dynamics of cancer cell survival post-chemotherapy.

Approximately 65% of breast cancer instances in the Philippines are identified in the advanced or late stages due to insufficient treatment and delayed detection. Among Filipinos, the five-year relative survival rate for breast cancer is a mere 44.4%. The Philippine Cancer Society highlighted that breast cancer is the leading cancer in terms of both new cases and fatalities, not only in the local context but also on a global scale. The statistics reveal 27,163 new cases annually, resulting in 9,906 deaths each year for both genders.

Medical Channel Asia presents the weekly Asian medical news bulletin, bringing you essential healthcare news from across the region. This week’s bulletin covers expired vaccines in Malaysia, illegal drugs in Singapore and monkeypox in Indonesia.